The short version of Certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
=== United Kingdom === The a2 Milk Company formed a joint venture with a major British milk supplier, Müller Wiseman Dairies (MWD), in November 2011 to process, market and sell its A1 protein-free products in Britain and Ireland. In June 2014 The a2 Milk Company reported it had 20 dedicated farms supplying milk for processing in the UK. In its first year the milk recorded £1 million in sales through 1,000 stores. On 1 January 2014, The a2 Milk Company exited its joint venture with MWD by acquiring MWD's stake for a "nominal" amount. In October 2019, the a2 Milk Company announced that it had decided to "discontinue a2 milk in the UK" and its products would only be available until the end of November 2019.
=== Kl--Ku === Martin Heinrich Klaproth (1743–1817), German chemist, who discovered uranium and zirconium, and contributed to the discovery of other elements Trevor Kletz (1922–2013), British promoter of industrial safety Aaron Klug (1926–2018), winner of the 1982 Nobel Prize in Chemistry for developing crystallographic electron microscopy Emil Knoevenagel (1865–1921) German organic chemist, known for the condensation reaction of carbonyl compounds with active methylene compounds Jeremy Randall Knowles (1935–2008), British physical organic chemist known for studies of chemical mechanisms, especially in enzyme catalysis William Standish Knowles (1917–2012), 2001 Nobel Prize in Chemistry for work on asymmetric synthesis, specifically in hydrogenation reactions Walter Kohn (1923–2016), 1998 Nobel Prize in Chemistry for contributions to the understanding of the electronic properties of materials Adolph Wilhelm Hermann Kolbe (1818–1884), German chemist known for Kolbe nitrile synthesis Izaak Kolthoff (1894–1993), Dutch-American chemist with abundant published research in diverse fields of analysis, the "Father of Analytical Chemistry" Arthur Kornberg (1918–2007), American biochemist, Nobel Prize in Chemistry (1959) for discovery of DNA polymerase Hans Kornberg (1928–2019), British biochemist known for research in microbial biochemistry Roger D. Kornberg (born 1947), 2006 Nobel Prize in Chemistry for elucidation of how genetic information from DNA is copied to RNA Teresa Kowalska (1946–2023), Polish chemist, specialized in the theory and application of chromatography Hans A.
=== Pharmacodynamics === Methylephedrine is a sympathomimetic and ephedrine-like agent. Ephedrine and related agents act as norepinephrine releasing agents and hence as indirectly acting sympathomimetics. In relation to this, methylephedrine stimulates α- and β-adrenergic receptors. The drug has bronchodilator and nasal decongestant effects. The occupancy of the dopamine transporter (DAT) by racemic methylephedrine has been studied.
Sources: en.wikipedia.org
=== Solid phase extraction === Solid phase extraction which separates long polymers like DNA from other substances found in the cells. This is similar to magnetic beads, where the solid phase is fixed and selectively binds a cellular component, allowing for its isolation.
=== Second stranding === Between January 9 and January 15, a storm tide dragged the carcass out to sea, but it washed ashore again on the next tide, on Crescent Beach, two miles to the south of its original location. Webb sent photographs of the mass, along with a description, to Joel Asaph Allen of the Museum of Comparative Zoology at Harvard. Allen apparently did not respond, but Webb's letter came to the attention of Prof. Addison Emery Verrill of Yale, at that time the foremost authority on cephalopods in the country. At first, Verrill suggested the carcass might represent the remains of a giant squid. In the January 1897 issue of the American Journal of Science he wrote:
== Fourier transform mass spectrometry == Fourier transform ion cyclotron resonance mass spectrometry was developed by Alan G. Marshall and Melvin B. Comisarow at the University of British Columbia in 1974. The inspiration was earlier developments in conventional ICR and Fourier Transform Nuclear Magnetic Resonance (FT-NMR) spectroscopy.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.